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ABSTRACT 
Malignant Pleural Mesothelioma (MPM) is currently an incurable cancer with a typical 
survival of 1 year from the time of diagnosis.  The recent genomic and transcriptomic 
characterisation of MPM presents new opportunities and challenges for MPM researchers. 
Recent advances in clinical and laboratory diagnostics, and proposals for an updated, 
data-driven, staging system, also present new challenges for clinicians and hospital 
services involved in MPM care. The aim of this review is first to introduce the reader to the 
topic of MPM, a disease that is causally linked to prior, typically occupational, exposure to 
asbestos fibres.  Secondly, we will discuss MPM from the clinical and laboratory 
perspectives, including reviews of current and evolving therapies and our present 
understanding of the molecular basis of the disease.  Finally, we will attempt to identify 
critical knowledge gaps that currently prevent more effective treatment, including the 
challenges involved in early detection and chemoprophylaxis. 
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INTRODUCTION 
Malignant Pleural Mesothelioma (MPM) is a locally invasive and currently incurable 
thoracic malignancy. A causative link to prior exposure to fibrous silicates (collectively 
termed ‘asbestos’) was first reported by Wagner and subsequently validated in workers 
previously exposed to mainly crocidolite and amosite [1], commonly in the ship-building, 
construction and mining industries . As a result, asbestos is prohibited in most countries, 
but a legacy of asbestos-insulated buildings remains. More worryingly, asbestos continues 
to be used without controls in many developing nations, and MPM will therefore remain a 
global threat for decades to come.  Recent years have seen major advances in the study 
of MPM, including the first detailed characterisation of the MPM tumour genome, the 
development of an updated, data-driven, staging system and a range of novel treatments 
and diagnostic tools. The aim of this article is review these advances from the clinical and 
laboratory perspectives, and to highlight remaining critical knowledge gaps. 
THE CLINICAL PERSPECTIVE 
Presentation 
Patients frequently present as an acute admission to hospital, often with breathlessness 
and/or chest pain associated with a unilateral pleural effusion [2,3]. MPM is more common 
in males and a long latency between asbestos exposure and disease is typical (40-50 
years). In females, a direct exposure history may be absent but indirect (non-occupational) 
contact may be traceable via a spouse or parent. Right-sided disease tends to 
predominate [4] but routinely available tests, such as Computed Tomography (CT) imaging 
[5,6], pleural fluid cytology [7] and closed pleural biopsies [8] offer poor sensitivity. Patients 
should therefore have early access to specialist diagnostics, including Local Anaesthetic 
Thoracoscopy (LAT), expert pathology review and the support a Mesothelioma Clinical 
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Nurse Specialist and MPM-focused multi-disciplinary team. 
 
Imaging  
The key investigations: Chest radiography, Ultrasound and Computed Tomography 
Chest radiography (CXR) will typically reveal a pleural effusion +/- loss of hemi-thoracic 
volume or a pleural mass. Pleural plaques are neither sensitive nor specific for MPM [4] 
but are useful to corroborate a history of prior asbestos exposure. Thoracic ultrasound 
(TUS) should be performed at the first opportunity, allowing estimation of effusion volume, 
identification of pleural nodules and planning of diagnostic/therapeutic fluid aspiration +/- 
subsequent LAT.  Computed Tomography (CT) scanning, with venous-phase contrast 
enhancement, may add valuable diagnostic information, but non-specific ‘benign’ features 
(e.g. a bland pleural effusion) should not dissuade invasive sampling. 35-46% [5,6] of 
patients with pleural malignancy will have a ‘benign’ CT report in routine practice, and the 
negative predictive value (NPV) of CT is particularly low when arterial-phase contrast (e.g. 
CT pulmonary angiography) or non-thoracic radiologist reporting is employed [6] (see 
Figure 1). Therefore, a new effusion +/- pleural thickening should prompt invasive 
sampling. 
The evolving role of PET-CT and MRI 
Positron Emission Tomography (PET)-CT is not commonly used for primary diagnostic 
purposes, but FDG uptake is typically higher in MPM than in benign pleural disease 
(reported mean SUVmax 6.5 (3.4)) vs. 0.8 (0.60), respectively [9]). PET-CT sensitivity is 
likely to be reduced in low volume tumours, therefore false negatives may occur in early 
stage MPM. Additionally, false positives may result from inflammatory or infectious 
pleurites, such as rheumatoid pleuritis, tuberculosis, and in patients who have had prior 
5 
 
talc pleurodesis [10,11]. These data are reflected in recent meta-analyses, which report 
variable performance in differentiating benign from malignant pleural disease (sensitivity 
81%-95%, specificity 74%-82%) [10,11]. A negative PET-CT should not, therefore, in 
isolation dissuade further investigation, e.g. by LAT, in patients in whom MPM is 
suspected. PET-CT can also be used to target the best site for histological sampling in 
suspected MPM. The randomised, multi-centre TARGET trial (ISRCTN14024829) is 
currently recruiting in the UK to determine whether this approach improves diagnostic yield 
in patients in whom a first biopsy has proven non-diagnostic.  
The primary role of PET-CT in MPM is as a staging tool, since is delivers the highest 
diagnostic accuracy (relative to CT and Magnetic Resonance Imaging (MRI)) for stage III 
disease [12], which has traditionally been the threshold for surgical intervention in previous 
studies. PET-CT is particularly usefully in identifying extra-thoracic metastases [13] but 
has limited sensitivity for both mediastinal node involvement (60%) and extra-pleural 
invasion (50%) [14]. MRI offers superior sensitivity to extra-pleural invasion [15] and 
should be considered if T4 disease is suspected prior to surgery (e.g. multi-focal chest wall 
invasion). Moreover, direct, histological assessment of the mediastinum should be 
considered, particularly in light of emerging data regarding the prognostic importance of 
mediastinal nodal involvement in MPM  (see ‘Staging’). Importantly, MRI also allows more 
precise estimation of pleural tumour volume [16] and acquisition of functional data [17] that 
may be useful in future T-staging and early detection strategies. 
Invasive Pleural Sampling 
Histological confirmation is currently recommended in all patients [18]. In those with 
effusion, LAT is preferable to closed pleural biopsy (e.g. Abram’s) since the latter offers 
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insufficient sensitivity (47% in a recent prospective study [8] and 57% in a series of 2893 
cases) [7], frequently resulting in repeated chest wall punctures which increase the risk of 
subsequent needle tract metastases. LAT is well-tolerated, safe (mortality 0.34% in 4736 
cases) and accurate (sensitivity 92.6%, specificity 100% in 1369 cases [19]), and allows 
simultaneous fluid evacuation and either talc pleurodesis or placement of an indwelling 
pleural catheter. General anaesthetic (GA) thoracoscopy offers similar performance but 
given the requirement for GA should be reserved for complex pleural spaces or used when 
LAT is unavailable or preferred by the patient. In patients with pleural thickening, CT- or 
TUS-guided cutting pleural biopsies offer high sensitivity (87%-94%) at minimal risk [7]. 
The latter can be performed on the table if LAT fails due to a fused pleural space [20].  
 
Pathology 
Laboratory Assessment of Diagnostic Samples 
International guidelines have not previously recommended fluid cytology for primary 
diagnostics. This reflects low sensitivity and specificity in earlier series. However, recent 
years have seen the development of a range of techniques [21], including fluorescent in 
situ hybridization (FISH) testing for homozygous deletion (HD) of the 9p21 locus 
(harbouring the p16/CDNK2A gene, which is frequently lost in MPM tumours [22]). HD of 
p16 offers high specificity (near 100% in the relatively small studies recently reported) in 
fluid cytology and pleural biopsies [23] (see Figure 1). However, this high specificity 
requires prior demonstration using immunocytochemistry that the cell population being 
tested is mesothelial in origin, since p16 loss is associated with other cancers. Overall, the 
sensitivity of fluid cytology, even with p16 FISH, remains low and pleural biopsies are 
required in negative cases.   
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Histological assessment of pleural biopsies may reveal an invasive front of MPM tumour 
cells. This should be confirmed using an appropriate panel of two positive mesothelial 
immune-histochemical (IHC) markers and two negative adenocarcinoma markers. 
However, sub-pleural invasion may not be present in early stage disease even if large, 
deep biopsies are taken, probably because of the spatially heterogeneous distribution of 
this component at this stage.  However, Hida recently reported that the presence of either 
p16 HD by FISH or loss of BRCA1-associated protein 1 (BAP1, encoded by the commonly 
inactivated BAP1 gene, [22]) IHC results in improved sensitivity (92.5%) [24] at high 
(100%) specificity, relative to assessment for sub-pleural invasion alone. While the data 
regarding these new molecularly-targeted laboratory tests should be interpreted with 
caution given the small samples sizes involved, their development may greatly improve the 
accuracy of early sampling for MPM.  
 
The importance of Histological Sub-type 
Histological sub-type is the strongest and most consistent predictor of survival in MPM [18] 
(see Figure 2). Epithelioid MPMs (50-60%) look morphologically similar to carcinomas and 
commonly present with pleural effusion, while sarcomatoid MPMs (10-20%) look like 
sarcomas and frequently present with pleural mass. These differing phenotypes and 
outcomes suggest epithelioid and sarcomatoid MPM are different diseases, making 
biphasic MPM (defined histologically by a mixture of epithelioid and sarcomatoid elements) 
difficult to explain. Comertpay recently reported that MPM is polyclonal based on the 
methylation status of the human androgen receptor gene [25]. Therefore, biphasic tumours 
may arise through synchronous evolution, or the intermingling of separate pools of 
epithelioid and sarcomatoid foci.  
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Biomarkers  
MPM diagnostics are difficult, outcomes are heterogeneous and radiological responses to 
therapy are difficult to define. A biomarker-directed approach is therefore attractive. The 
most promising circulating diagnostic markers are mesothelin (or serum mesothelin-related 
protein (SMRP) [26], fibulin-3 [27],  high mobility group box-1 (HMGB-1) [28] and an 
aptamer-based proteomic classifier [29].  Of these, mesothelin is the most widely studied 
and the only marker with FDA approval. However, a large meta-analysis reported poor 
sensitivity (32%) at 95% specificity [26], so negative results are of little value, particularly in 
non-epithelioid disease. The other markers require prospective validation, which is 
currently ongoing [30]. The most important future role for circulating markers may be as 
early indicators of treatment response, given the cost of emerging therapies.  
 
Staging  
The first globally adopted MPM staging system was defined in 1994, based on expert 
consensus and relatively small surgical series [31]. In assigning a T-stage, much emphasis 
was placed on the visible extent of pleural surface involvement at surgery and the system 
proved difficult to use in routine practice, where most patients are managed non-surgically. 
Subsequent validation studies confirmed poor separation of early stage (T1-T2) cases and 
significant discordance between surgical and clinical staging results [32]. This prompted a 
large international prospective staging project, which included more non-surgically treated 
patients and culminated recently in recommendations for an updated staging system (see 
Figure 3).  The proposed TNM 8 system delivers improved prognostic performance and 
should be easier to deliver since surgical observations have become less important for 
allocation of T-stage, which is now based on ‘clinical’ (predominantly imaging) results [33]. 
In addition, under the new system, nodal staging [34] is better aligned with documented 
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patterns of pleural drainage from animal and human cadaveric studies, having been 
previously based on patterns of lung cancer nodal spread. Animal studies demonstrate 
that the parietal pleura drains ventrally towards nodes along the internal thoracic artery 
and dorsally towards the internal intercostal artery nodes, near the heads of the ribs [35]. 
This probably facilitates direct drainage of malignant MPM lymph into mediastinal 
(previously N2) glands, not necessarily involving intrapulmonary (previously N1) glands. 
This data is concordant with human cadaveric studies reported by Okiemy [36] and is 
reflected in the observations of Rahman, who reported frequent involvement of mediastinal 
(previously N2) nodes in patients with pleural invasion in the absence of intrapulmonary 
(previously N1) nodes [37].  Furthermore, Rusch et al recently reported no difference in 
survival between patients with intrapulmonary (previously N1) vs. mediastinal (previously 
N2) disease (median survival 17 months versus 13 months, HR 1.11 (p=0.2771)), but a 
significant difference in those with no node involvement (N0) relative to those with any 
node involvement’ (previous N1 HR 1.26 for, p=0.0071 vs. N0; previous N2 HR 1.40, p 
<0.0001 vs. N0) [38]. As a consequence, the updated staging system proposes merging 
the previous N1 and N2 categories into a single new N1 grouping [34], emphasising the 
importance of any node-positive disease (see Figure 3). While it is hoped this system will 
perform more efficiently it continues to be based on predominantly surgical data, and has 
yet to benefit from large-scale staging studies testing the relative value of pathways 
combining modern tools such as PET-CT, MRI and invasive mediastinal staging. 
 
Current and Emerging Therapies  
In this section, the evidence for a range of MPM treatments is reviewed. The focus is on 
systemic, radiation and surgical techniques. However, effective management of associated 
pleural effusion is extremely important in symptomatic patients and may be the only 
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treatment delivered in many cases. In a recent randomised study involving all forms of 
malignant pleural effusion, talc slurry (TS) pleurodesis and indwelling pleural catheter 
(IPC) placement delivered equivalent rates of pleurodesis success and symptom control 
[39], although non-comparative data suggest that pleurodesis may be less successful in 
patients with MPM [40]. Ideally, patients should be offered a choice between an attempt at 
TS or IPC insertion, based on the relative risks and benefits of these techniques, unless 
non-expansile (trapped) lung is clinically obvious, in which case an IPC is preferable [41].  
 
Palliative Chemotherapy 
In 2003, Vogelzang reported an objective radiological response (ORR) in 41% of patients 
treated with a platinium/anti-folate doublet, comprised of Cisplatin and Pemetrexed (Cis-
Pem). This was associated with an overall survival (OS) benefit of 2.8 months, relative to 
treatment with Cisplatin alone [42]. Comparable results were subsequently reported using 
an alternative anti-folate, Raltitrexed, in a similarly designed Phase III trial, although this 
drug is no longer available. Carboplatin(Carbo)-Pem has been shown to offer similar 
efficacy to Cis-Pem [43] in a post-licensing comparison and this combination has been the 
only licensed MPM therapy since, and the comparator for all Phase III trials of novel 
agents. This evidence base is clearly weakened by the lack of randomised evidence of a 
survival benefit over no chemotherapy (i.e. all supportive care), although indirect evidence 
such as improved survival in MPM registries might support this [44]. The placebo-
controlled MSO1 failed to demonstrate any survival benefit for chemotherapy relative to 
ASC, but importantly involved an older regimen not including an anti-folate (Mitomycin, 
Vinblastine & Cisplatin) and failed to reach its adjusted recruitment target [45].  
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As with many therapies, the ORR to Cis/Carbo-Pem has proven lower in post-licensing 
studies (13%-26.3%[43,46]). When combined with the lack of a reliable predictive 
biomarker [47], an elderly patient population (64% of UK patients are > 70 years old) [3] 
and evidence of short survival in chemo-resistant patients [48], cautious use of Cis/Carbo-
Pem in some centres is understandable. In a recent audit in England & Wales, treatment 
rates varied from 46% to 71% (see later website link for UK National Lung Cancer Audit 
Mesothelioma Report (2016)). This variation leads to associated challenges in recruitment 
of large numbers of patients to 1st line trials involving Cis-Pem, and 2nd line studies that 
require previous treatment with Cis-Pem.  A reliable predictive marker for Cis-Pem 
response would therefore be the first and most important step in delivering stratified MPM 
management in the future.  
 
In the recently reported MAPS study [49], the addition of Avastin (Bevacizumab), a 
vascular endothelial growth factor (VEGF) inhibitor demonstrated superior OS, relative to 
Cis-Pem alone. However, the OS gain was modest (2.7 months) with significant 
associated side effects (71% of patients experienced Grade 3-4 adverse events) and 
unfortunately, no predictive biomarker to assist in patient selection. At present, the MAPS 
triplet regime has yet to be licensed in Europe, the US or the UK. In our opinion, while 
chemotherapy is a valuable option for some patients, new approaches are urgently 
needed. Chemotherapy may, for example, prove to be an important part of future multi-
modality immunotherapy schedules, given its ability to deplete tumour promoting 
immunosuppressive cells. Maintenance [50] and second-line chemotherapy studies have 
previously been negative [51] and no standard of care exists in this context. 
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Surgery 
Several previous non-randomised series reported long-term survivors following extra-
pleural pneumonectomy (EPP), which involves removal of the diseased pleura, in addition 
to the lung, pericardium and hemi-diaphragm, usually as part of a multi-modality regime 
including neo-adjuvant chemotherapy and adjuvant hemi-thoracic radiotherapy [18].  
However, these data were systematically biased in favour of EPP, since they incorporated 
stringent surgical selection criteria. The Mesothelioma and Radical Surgery (MARS) trial 
was a randomised feasibility study of EPP, as part of multi-modal approach. MARS took 
over 3 years to randomise 50 patients and failed its feasibility end-points, but importantly 
demonstrated excess mortality in the EPP arm (adjusted HR 2·75 (1·21–6·26; p=0·016)) 
[52].  A recent meta-analysis also reported higher 30-day and 2-year mortality following 
EPP, relative to lung-sparing (pleurectomy/decortication (P/D)) surgery [53]. Despite much 
initial debate, the potential for harm associated with EPP is now generally accepted, 
prompting a move towards a lung-sparing approach.  Lung-sparing surgery for MPM has 
been variably defined but should be categorised according to the consensus statement 
jointly made by the International Mesothelioma Interest Group and the International 
Association for the Study of Lung Cancer in 2011 [54]. This document defines P/D as a 
parietal and visceral pleurectomy performed with the intention of removing all visible 
tumour. Extended P/D additionally includes resection of the diaphragm and/or pericardium 
if these surfaces are affected. In contrast, Partial Pleurectomy (also referred to as Partial 
P/D) may involve removal of parietal and/or visceral tumour, potentially facilitating re-
inflation of a non-expansile (trapped) lung, but always leaves visible tumour behind, and is 
generally performed as a combined diagnostic and palliative procedure. In 2014, the 
MesoVATS trial reported no survival advantage in patients allocated to Partial Pleurectomy 
(HR for death at 1-year 1·04 [95% CI 0·76–1·42]; p=0·81) relative to a those treated by a 
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simple TS pleurodesis. Partial P/D was also associated with a longer hospital stay, more 
complications and increased cost [55]. A large non-randomised Italian series has also 
recently reported inferior OS in patients treated by Partial P/D relative to Extended P/D, 
although this may reflect the selection criteria of the surgeons involved [56].  Meso-TRAP 
is currently recruiting in the UK to specifically determine the effect of Partial P/D on 
symptoms in patients with symptomatic non-expansile (trapped) lung, since these were 
largely excluded from MesoVATS [55]. At present, Meso-TRAP is a randomised feasibility 
study, which if positive will lead to a future Phase III trial randomising patients between 
Partial P/D and IPC placement.  Also in the UK, the MARS-2 trial (NCT02040272) is 
currently recruiting patients with potentially resectable disease, having completed an initial 
feasibility phase. The primary objective of this important Phase III study is to determine the 
effect of Extended P/D, in combination with Cis-Pem, on OS and quality of life, relative to 
Cis-Pem alone. While the outcomes of these studies are eagerly awaited, surgery has at 
present, no proven therapeutic role in MPM. 
 
Radiotherapy 
Intensity-modulated radiotherapy (IMRT) now allows effective moulding of large RT doses, 
even to the complex morphology of the pleura. However, some of the apparent radio-
resistance associated with MPM may reflect intrinsic radio-resistant tumour biology, and 
development of effective radio-sensitizers may be necessary for maximum effect. 
Combinations of RT with relevant agents, e.g. DNA-damage repair inhibitors (e.g. PARP 
inhibitors) and/or immunotherapies may deliver new treatment options. For example, 
fractionated RT has been shown to augment the response to CTLA-4 checkpoint inhibitors 
in pre-clinical cancer models [57]. 
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For decades, palliative RT has been routinely offered for MPM pain, despite widely varying 
response rates (0-69%) and an inconclusive systematic review in 2014 [58]. In 2016, the 
SYSTEMS study, a multicentre, single-arm, phase II study reported an improvement in 
pain in only 35% of patients following 20Gy/5♯ [59], which is the standard dose in most 
centres. SYSTEMS-2, a randomised Phase III study is currently recruiting, comparing 
dose escalation (to 36Gy/6♯) to 20Gy/5♯, for which there is now robust efficacy data based 
on the results of the original SYSTEMS study.  
 
Radical RT has most commonly been used as part of multi-modality strategy based 
around EPP. Most previous studies were therefore non-randomised case series, however 
these demonstrated that up to 54Gy/30♯ could be delivered post-EPP and that Radiation 
Pneumonitis (RP) rates could be minimised using IMRT [60]. In 2015, the randomised 
SAKK 17/04 trial failed to detect any difference in loco-regional relapse-free survival in 
patients allocated to IMRT after EPP, but the study was under-powered as only 73% 
patients had been allocated to IMRT at early closure [61].  Furthermore, in the post-EPP 
era, it is more important that radical RT can be delivered safely with two lungs in-situ. 
Therefore, Rimner’s 2016 report of tolerable IMRT toxicity (Grade 3 RP in 2/27 (7%)) 
following P/D is important data [62] and a phase III study is planned.  
 
Previous studies regarding the effect of prophylactic RT on the incidence of procedure-
tract metastases were contradictory and relatively small. In 2016, the SMART trial reported 
no reduction in procedure-tract metastases incidence in 203 patients randomised equally 
between immediate (prophylactic) RT and deferred RT if a tract metastasis developed   
[63]. Results from the broadly similar and recently completed PIT (Prophylactic Irradiation 
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of Tracts) trial are expected imminently, but at present there is little to support this 
approach. 
Mesothelin-targeted agents  
Mesothelin is an attractive, relatively selective target for MPM therapy since it is over-
expressed in most MPM tumours and expression is limited to normal pleural, peritoneal 
and pericardial surfaces. Immunotoxins target this expression specifically, including SS1P 
and the more recently reported RG7787 [64]. SS1P is a recombinant immunotoxin 
comprised of an anti-mesothelin variable fragment and the PE38 portion of Pseudomonas 
exotoxin A.  The agent is cytotoxic to mesothelin-expressing cell lines but ineffective as 
monotherapy, due to development of anti-SS1P antibodies in over 90% patients. In 2013, 
Hassan and colleagues reported major regressions in 3/10 patients treated with a 
combination of SS1P and cyclophosphamide and pentostatin [65], which selectively 
deplete T- and B-cells respectively, leaving myeloid cells relatively preserved. Several 
other strategies targeting mesothelin are currently the subject of open trials. These include 
a chimeric monoclonal antibody to mesothelin (amatuximab) [66] and a mesothelin tumour 
vaccine (CRS-207) [67]. A randomised Phase II, 2nd line trial of the drug-antibody 
conjugate, anetumab ravtansine (comprised a tubulin inhibitor bound to SS1P) recently 
reported failure to meet its primary end-point (Progression Free Survival) [68]. While the 
ongoing studies in this area may yet validate highly targeted approaches to MPM therapy 
this result is a significant disappointment. If ultimately fruitful, the potential utility of serum 
mesothelin as a predictive and response marker [64] could be considerable advantage for 
mesothelin-targeted agents. 
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Immunotherapy  
Immunotherapy offers great hope for MPM patients, after exciting positive clinical trials in 
other cancers. However, recent land-mark data demonstrate that mutational burden is low 
in MPM [22] and success may require multiple agents or combination with other 
modalities. Lung-sparing surgery may, for example, have an important role to play by 
reducing tumour bulk and creating a host environment more amenable to immunotherapy 
(releasing tumour neo-antigens, reducing the ratio of tumour cells to T-effector cells). 
Comprehensive reviews of this rapidly evolving field have recently been published [69-71]. 
Our impressions of the progress so far and the best hopes for future success are laid out 
below. 
 
Cytokines, including interleukins (ILs) and interferons (IFNs), activate host immune 
response to viruses and cancer cells. Almost 20 years ago, Astoul reported tumour 
regression in selected patients (12/20 (54%), all epithelioid) in response to intra-pleural IL-
2. However subsequent clinical data have been contradictory [72]. Intra-pleural IFN-γ has 
previously produced a 20% response rate [73], but excessive (flu-like) toxicity has greatly 
limited further study. More recent studies of adenovirus-encoding IFN-β (Ad–IFN-β) [74,75] 
and IFN-α2b (Ad–IFN-α2b) [76] suggest these cytokines may have useful activity in MPM. 
However, their effects are severely limited by development of adenovirus-neutralizing 
antibodies and the immunosuppressive tumour microenvironment. Importantly, a recent 
Phase I study has reported acceptable side-effects of a multi-modal approach to address 
this, combining chemotherapy (promoting tumour neo-antigen exposure), COX-2 inhibition 
(suppressing the immunosuppressive tumour micro-environment) and IFN-α2b 
immunogene therapy [77]. Future randomised efficacy studies are therefore expected. 
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The considerable therapeutic potential of Chimeric Antigen Receptor (CAR)-T 
Lymphocytes in MPM has been explored over recent years. CARs specific to MPM tumour 
antigens can be introduced into circulating T-lymphocytes ex-vivo, thereby directing their 
cytotoxic potential towards antigen-bearing MPM cells on re-infusion. These products are 
Major Histocompatibility Complex (MHC)-independent, meaning they can be utilised in 
diverse populations. Anti-mesothelin and anti-fibroblast activation protein (FAP; which is 
expressed ubiquitously in the MPM tumour microenvironment) CAR T-lymphocytes have 
both been shown to induce regression in MPM xenograft tumour models and can be 
delivered locally, to the pleura, using an indwelling pleural catheter [78,79].  Several Phase 
I studies testing the safety of these approaches are currently underway.  
 
Immune checkpoints exist to dampen immune responses to native tissues and are 
generally mediated by receptor-ligand interaction. Allison was the first to discover that 
established tumours expressed cytotoxic T-lymphocyte antigen-4 (CTLA-4) and this 
mediated an immune-tolerant, pro-tumour effect. This spawned the development of CTLA-
4 inhibitors as cancer therapies. However, a recent Phase I study of the CTLA-4 blocker, 
tremelimumab, showed ORR in only 2/29 patients, and no extension in OS in a 
subsequent Phase IIb (DETERMINE) trial [80].  Programmed Death receptor-1 (PD-1) is a 
T-lymphocyte associated checkpoint that has emerged as an alternative potential target for 
MPM therapy [71]. PD-1 is expressed on effector lymphocytes, while its natural ligands 
PD-L1 and PD-L2 are expressed on tumour cells or in the surrounding microenvironment. 
PD-1/PD-L1 blockade unleashes down-regulated T-cells, mediating tumour rejection. PD-1 
expression is highly variable in MPM cohorts (20-70% in previous studies), with stronger 
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expression in sarcomatoid sub-types and an inverse correlation with survival [71]. Alley et 
al recently reported interim results of the KEYNOTE-028 Phase Ib trial of the PD-1 blocker, 
pembrolizumab, summarising responses in 50 patients with unresectable, PD-L1 positive 
MPM (defined by >1% PD-L1 expression in the tumour or surrounding stroma). This 
analysis suggests significant potential activity, including PR and stable disease (SD) rates 
of 20% and 52%, respectively and a median duration of response of 5·6 months (95% CI 
3·6–12·0)[81].  An open-label Phase II study of pembrolizumab is currently recruiting, and 
importantly includes subjects without PD-L1 expression, in whom some responses have 
been reported. One of the aims of this trial is to determine a threshold of PD-L1 expression 
for anti-PD-L1 activity [82]. Given the cost and potential duration of these treatments this 
data will be of enormous interest to funders and regulatory bodies. Early phase studies of 
nivolumab and avelumab have also been reported, with disease control rates (PR + SD) of 
50-57%, in cohorts without entry criteria based on PD-L1 expression, as recently 
summarised by Mansfield [71]. In addition, pre-clinical studies on other, so far neglected, 
elements of the checkpoint pathway (e.g. PD-L2, LAG-3, TIM-3)[69,70] may yield further 
targets for MPM treatment, and a means of long-term control may evolve from this exciting 
field of research. 
Molecularly targeted agents  
For reasons described below, there are few obvious targets for direct pharmacological 
inhibition in MPM.  Phase II studies involving ertolinib [83] and gefitinib [84] (small- 
molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)) and 
defactinib (a focal adhesion kinase (FAK) inhibitor) have previously been negative [85]. 
However, interest in this field is currently increasing, following positive recent results in the 
Phase III MAPS study, involving the VEGF inhibitor, bevacizumab [49](see ‘Palliative 
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Chemotherapy’) and the Phase II LUME-Meso, study, involving the multi-targeted 
angiokinase inhibitor, nintedanib. In the latter, addition of nintedanib to 1st line Cis-Pem 
resulted in improved median PFS (from 5.7 (5.5 - 7.0) to 9.4 (6.7 - 11.2) months, (HR for 
0.54 (0.33 to 0.87), p = 0.01) and a Phase III study is currently ongoing [86]. 
 
THE LABORATORY PERSPECTIVE 
General molecular features, new sub-types and driver mutations 
A broad molecular characterization of 216 cases of MPM was recently published [22]. 
Based on exome sequencing, few protein-altering mutations were reported (average 
24±11 per tumour). This is low relative to most cancers, particularly lung cancer, where 
coding mutations typically number in their hundreds [22]. Indeed, the mutation signature of 
smoke-related DNA-damage was entirely absent, suggesting that smoking does not 
contribute to MPM. Instead, a reactive oxygen species (ROS)-induced DNA damage 
signature predominated, consistent with known effects of asbestos fibres and 
macrophage-driven inflammation [87].   
 
Unsupervised clustering of transcriptomic data revealed four distinct tumour subtypes, 
rather than the histologically defined previous three. Epithelioid and sarcomatoid 
classifications were retained but biphasic tumours were split into biphasic-E and biphasic-
S [22]. 68% of tumours histologically classified as epithelioid were molecularly classified as 
biphasic-E, which had a significantly worse prognosis than other molecular sub-types. 
Sarcomatoid tumours also expressed higher levels of PD-L1 and had higher estimated 
numbers of immune-inhibitory M2 macrophages and infiltrating lymphocytes. This 
suggests this subgroup may be more amenable than other sub-types to immunotherapy 
[22] and hints that this new data may allow better stratification of patients in future studies.   
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One of the most striking molecular features identified was the paucity of recognizable 
driver mutations in well-characterized oncogenes, in particular those for which small 
molecule inhibitors are presently available. It is thus highly unlikely that large numbers of 
MPM patients will benefit from off-the-shelf targeted therapeutics, as borne out in previous 
molecularly-targeted studies [85]. Instead, MPM is typified by loss-of-function mutations in 
tumour-suppressor genes and mutations of unknown consequence.  This lack of obviously 
‘druggable’ targets presents the greatest single challenge to the immediate development 
of novel treatments. 
 
The main genetic suspects in MPM 
BAP1 
Germline mutations of BAP1 give rise to multiple tumours including MPM, as recently 
reviewed elsewhere[88], while sporadic BAP1 mutations occur in approximately 50% of 
cases [89].  BAP1 is a de-ubiquitylating enzyme that removes ubiquitin tags from substrate 
protein targets, including BRCA1-associated protein, BARD1, and a transcription co-factor 
HCF1 [90],[91]. Ubiquityaltion has multiple roles in regulating protein function and signal 
transduction and the effect of BAP1 loss on each of its substrates will need to be 
empirically determined [92]. Loss of BAP1 also alters polycomb-regulated gene expression 
with potentially far-reaching effects [93] and tailored therapeutic strategies will be required 
to target these pathways effectively. 
 
CDKN2A/B 
Deletion of CDKN2A occurs in up to 50% of MPM cases [94].  CDKN2B is syntenic with 
CDKN2A on chromosome 9, so the vast majority of cases exhibit loss of both loci [95].  
Both genes encode inhibitors of cyclin-dependent kinases (p16 by A; p15 by B), which 
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serve to block or delay progression through the cell cycle. The frequency of these 
deletions suggests that cellular senescence may play an important role in delaying the 
emergence of MPM, and suppression of senescence could represent a “gate-keeper” 
event in pathogenesis.  Notably, cellular senescence is also induced by oxidative damage 
and both the inflammatory microenvironment and asbestos fibers are known sources of 
ROS [96].   
 
NF2/LATS1 – The Hippo Pathway 
Loss of NF2 (Neurofibromatosis type 2, or Merlin) in MPM was first reported in 1995 and 
occurs in 19-50% of cases [22]. NF2 is part of the Hippo signalling pathway, which is 
dysregulated in a various cancers [97]. In MPM, mutations are found in multiple Hippo 
genes including NF2 (more frequent in sarcomatoid and biphasic-S), LATS1 and MST1 
(more frequent in epithelioid and biphasic-E). Cross-talk between specific pathway 
components and other signalling pathways, such as WNT, TGF-β and AMPK [98,99] may 
determine the eventual phenotypic outcome and better understanding is required for 
development of precision therapies. 
 
SETD2 
SET domain histone methyltransferases are epigenetic regulators of gene expression.  
SETD2 tri-methylates histone H3 on lysine 36, a modification that is associated with active 
transcription [100]. This gene was one of several novel MPM-associated mutation targets 
recently reported,along with other members of the SETD gene family [22]..  A distinct role 
for SETD2 in methylation of microtubules during mitosis and cytokinesis was recently 
described:  Deletion of SETD2 ablated lysine 40 methylation of γ-tubulin, resulting in 
mitotic spindle defects and aneuploidy [101].  Whole and partial chromosome number 
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alterations are widely reported in MPM and mutations in SETD2 provide a plausible 
mechanistic explanation for at least some of this observed aneuploidy. 
 
TP53 
Tp53 is the single most-frequently mutated gene across all cancers, yet its mutation rate in 
MPM is relatively low, present in only 8% of MPMs and, strikingly, in none of the epithelioid 
tumours analyzed by Bueno & colleagues [22].  It is possible that loss of p14ARF as part 
of the CDKN2A locus relieves the selective pressure to inactivate p53 although DNA 
damage can activate p53 independently of p14ARF status [102]. Alternatively, p53 may 
play a non-canonical role in this disease.  In particular, recent work has shown that 
functional p53 plays an important role in protecting cells from oxidative damage [103]. 
Oxidative stress in MPM is thought to derive from asbestos-driven chronic inflammation 
and reactive oxygen species (ROS) can alter protein function and promote ectopic cell 
proliferation [104]. However, high levels of ROS can be cytotoxic. Given the potential role 
of ROS in driving disease development or progression it is possible that MPM tends to 
select for wild-type p53 in order to suppress ROS-driven cytotoxicity.  It may be possible to 
exploit this feature of MPM through strategies that drive or enhance p53-dependent 
apoptosis, for instance via emerging BH3-mimetic therapies [105]. However, such an 
approach would not be without its risks as widespread activation of p53 can be harmful to 
normal tissues [106]. 
 
CRITICAL KNOWLEDGE GAPS AND FUTURE DIRECTIONS 
The Development of Effective Therapies 
The recent genetic characterization of MPM constitutes a watershed moment for MPM 
research, but has also exposed key knowledge gaps. Few of the genetic players in MPM 
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are well understood and little is known about how they contribute to the disease.  For 
example, what targetable vulnerabilities arise from mutation of the tumour suppressors 
commonly identified? What role does the tumour microenvironment play in supporting 
disease?  Does asbestos contribute to MPM beyond the acquisition of key mutations? Can 
immunotherapy be exploited despite the low mutation burden? These and other questions 
require the development and widespread adoption of better in vitro (patient-derived, 3D 
and co-culture) and in vivo (combined use of conditional alleles with asbestos exposure) 
models that a) permit investigation of early disease evolution and b) better reflect response 
to therapies than current 2D monoculture.  Fortunately, the low number of common 
mutations will focus research efforts on a small number of pathways and, with the 
appropriate tools, progress is poised to accelerate further. 
 
Early Detection  
Additional but equally important questions surround the role of early detection of MPM, 
which was identified as a key priority for patients during the recent James Lind Alliance 
Priority Setting Partnership (see associated website information). However, based on the 
literature to date, we can infer that in incident cases of MPM only 1/3 of patients will have 
visible pleural plaques [4] and only 2/3 will have a positive Mesothelin blood test (the 
current best of the circulating markers) [26] or a CT scan with obvious morphological 
evidence of pleural malignancy [5,6]. This suggests that we do not currently have the 
necessary detection tools to run an accurate screening programme, particularly since the 
prevalence of MPM will be considerably than lower in this setting than in the symptomatic, 
incident populations included in the studies referenced above. This is reflected in 2 
previous negative screening studies, in which few cases were detected [107,108]. 
However, these used low-dose non-contrast CT, which is insensitive to early stage MPM 
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and recruited a relatively unselected cohort of ex-asbestos workers. Therefore, if early 
detection/screening is to be successful more accurate diagnostic tests, and better 
selection criteria are urgently needed. Patients, grant funders and ethics committees also 
need to be confident that the benefits of screening would be worth the risk and costs, 
including the burdens placed on those with false positive results. At present this is 
probably not the case but may change over coming years. Therapeutic options appear 
likely to increase in the near future. MRI may also prove to be a better screening tool than 
CT, since it does not involve exposure to ionising radiation and offers superior precision 
[16] and complementary (but as yet unproven) diagnostic functional end-points [17]. In 
addition, recent data suggests that reconstruction of cumulative life-time asbestos 
exposure and accurate modelling of lifetime MPM risk is possible [109], and may better 
select individuals most likely to benefit. This selection may be further improved by use of 
novel biomarkers such as ENOX2 protein transcript variants, which can be detected in the 
serum of patients destined to develop MPM up to 10 years prior to diagnosis [110]. Earlier 
detection is likely to improve outcomes, not least by allowing the maximum possible 
number of patients to enter clinical trials of new treatments. Given the considerable 
expansion of MPM research over recent decades we believe this should be pursued 
aggressively, in parallel with, not following the development of effective therapies. 
 
Chemoprophylaxis 
Chemoprophylaxis involves use of preventative therapies with minimal or no side effects to 
modify the biology associated with carcinogenesis, thereby reducing cancer incidence. 
Unlike screening, chemoprophylaxis does not require development of expensive 
diagnostic tools but could utilise similar lifetime MPM risk models [109] to identify those 
most likely to benefit. MPM is typically preceded by decades of chronic asbestos-related 
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inflammation and the production of ROS [87], which in turn has recently been associated 
with the common genetic lesions found in MPM tumours [22]. However, previous studies 
using plausible chemoprophylactic agents have been disappointing. In a transgenic mouse 
model of peritoneal mesothelioma, driven by SV40 Tag and induced by asbestos injection, 
anti-inflammatories (aspirin and cyclo-oxygenase-2 (COX-2) inhibitors) and anti-oxidants 
(Selenium, Vitamin A or Vitamin E) did not demonstrate useful chemoprophylactic effects 
[111]. In a xenograft (immunodeficient) peritoneal MPM mouse model, aspirin has recently 
been reported to suppress HMGB-1 levels and tumour growth [112], which may be 
relevant since HMGB1 is implicated in MPM pathogenesis and detectable blood at 
presentation in many patients [28]. We agree with others who recently encouraged a re-
evaluation of chemoprophylaxis in MPM [113], but acknowledge the time and large sample 
sizes required to perform meaningful studies in this area. More precise pre-clinical data 
are required to design future human studies. This is likely to require high-throughput drug 
screening combined with animal models that more accurately recapitulate early disease 
biology, ideally in an immunocompetent system. MPM is preceded by up to 2 years by 
‘Benign Asbestos Pleural Effusion (BAPE)’ (or Benign Fibrinous Pleurisy) in a significant 
minority of patients [114]. Since the nutritive and potentially pro-tumourigenic nature of 
pleural effusion has only recently been described [115], this component of early MPM 
biology may not have been accounted for in previous pre-clinical studies. Studies involving 
sequential biopsies in patients with BAPE may therefore better define the key events 
involved in the transition from chronic pleural inflammation to MPM, and should be 
considered. 
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CONCLUSION 
There has been enormous progress in MPM over the last decade, including the 
development of an updated, data-driven staging system and the rigorous assessment of 
new (and some older) therapies in global clinical trials.  Better diagnostic tools and 
methods for palliation of associated pleural effusion are now available. The MPM tumour 
genome has recently been characterised in detail for the first time, opening up new 
opportunities for MPM researchers and new hope for patients and their families. Further 
significant progress is therefore expected in the near future. 
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SEARCH STRATEGY AND SELECTION CRITERIA 
References for this review were identified by searching PubMed using the search term 
‘Mesothelioma’, combined with one or more additional terms depending on the area of 
interest, e.g. ‘Chemotherapy’, ‘Surgery’, ‘Immunotherapy’, ‘Biomarker’. The authors’ 
publication libraries were also reviewed and relevant abstracts selected from recent 
scientific meetings. Only references since 2000 were included.  
 
USEFUL WEBSITES 
• Outcomes of the recent James Lind Alliance Priority Setting Partnership, with 
regard to current research priorities in MPM: 
http://www.psp.nihr.ac.uk/mesothelioma  
• Recently published (December 2016) national audit data regarding outcomes in 
MPM patients diagnosed in England and Wales during 2014: 
https://www.rcplondon.ac.uk/projects/outputs/national-lung-cancer-audit-pleural-
mesothelioma-report-2016-audit-period-2014  
• The Mesothelioma Applied Research Foundation (formerly known as MARF): 
http://www.curemeso.org/  
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FIGURE LEGENDS 
Figure 1 
Panel A & B: Axial Computed Tomography images of a patient with diagnosed with early 
stage Malignant Pleural Mesothelioma (MPM) in our unit. These demonstrate a large 
pleural effusion (PE), but no obvious areas of pleural thickening. Panel C & D: Local 
Anaesthetic Thoracoscopy (LAT) images recorded in the same patient demonstrating 
widespread parietal pleural tumour (some highlighted by white arrows) after complete 
evacuation of the large pleural effusion. Note the descending thoracic aorta (Ao) also 
covered by tumour, the deflated left lower lobe (LLL) and the left hemi-diaphragm (LHD). 
Panel E: H&E staining (x 20 magnification) of parietal pleural biopsies taken during LAT, 
demonstrating an invasive front of proliferating mesothelioma cells, extending from the 
pleural surface (not present in the image because of the depth of the biopsy) into the sub-
pleural fat (red arrows). The pleural surface lies just beyond the black arrow in the top right 
corner. Islands of invasive tumour cells are also highlighted (*). Panel F: The lower image 
demonstrates homozygous deletion of the P16 locus by fluorescent in-situ hybridisation 
(FISH) in exfoliated MPM cells in pleural fluid. Homozygous deletion requires loss of 2 red 
signals in at least 20% of nuclei. There is loss of one red signal in heterozygous deletion.  
The lower image shows a normal p16 test for comparison, demonstrating benign 
mesothelial cells, which exhibit two green signals (chromosome 9 centromeric probe) and 
two red signals (locus-specific probe to P16/INK4A (CDKN2A) gene). 
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Figure 2 
Baseline clinical data and overall survival (OS) outcomes were recorded retrospectively in 
404 patients diagnosed with Malignant Pleural Mesothelioma (MPM) in the West of 
Scotland, between January 2008 and April 2017. In 370/404 OS data were available. 
Kaplan-Meier methodology was used to determine the impact of histological subtype on 
OS in 342/404 (28/404 patients in whom a histological sub-type was not recorded were 
excluded). OS was significantly influenced by histological sub-type (log rank p < 0.0001, 
chi square 27.5); OS was longest in patients with epithelioid MPM, intermediate in biphasic 
cases and shortest in sarcomatoid MPM (log rank for trend p < 0.0001, chi square 26.8). 
Relative to epithelioid MPM, the log-rank hazard ratio (HR) for death in patients with 
sarcomatoid (HR 1.93 vs epithelioid, p < 0.0001) and biphasic MPM (HR 1.75, vs 
epithelioid, p = 0069) were significantly increased. HR for death was not different between 
sarcomatoid and biphasic cases (HR 1.14, p > 0.05).  
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Figure 3 
Summary of the current staging system of Malignant Pleural Mesothelioma, as presented 
in the current 7th edition of the staging manuals of the Union for International Cancer 
Control (UICC) and the American Joint Commission on Cancer (AJCC). The proposed 
revisions for the imminent 8th edition are presented alongside (with updated descriptors 
highlighted in pink), in addition to updated stage groupings and associated overall survival 
curves. The survival curves are reproduced from Rusch et al. J Thorac Oncol 2016;11(12): 
2112-2119. IM; internal mammary, PC; peri-cardiac, PD: peri-diaphragmatic, SC; supra-
clavicular. 
 
 
 
 
 
 
 
 
 
 
 
 
